Roche makes class-first push into thyroid eye disease with new FDA nod for Enspryng

Roche's Enspryng, an IL-6 receptor agonist, received FDA approval as the first at-home subcutaneous treatment for thyroid eye disease (TED), offering a new mechanism and self-injection convenience against competitors Tepezza and Lumvoa. The approval is based on phase 3 trial results showing meaningful improvements in eye bulging and double vision in active TED patients.

This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it.